

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115972 A1

(51) International Patent Classification⁷: **C07C 237/28**,
C07D 207/06, 215/16, 217/22, 295/04, 295/16, A61K
31/166, 31/40

(21) International Application Number:

PCT/SE2005/000754

(22) International Filing Date: 20 May 2005 (20.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0401342-1 25 May 2004 (25.05.2004) SE

(71) Applicant (for all designated States except US): **AstraZeneca AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JIN, Shujuan** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **LIU, Ziping** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **MILBURN, Claire** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **TOMASZEWSKI, Mirosław** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **WEI, Zhong-yong** [CA/CA]; AstraZeneca R

& D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA). **YANG, Hua** [CA/CA]; AstraZeneca R & D Montreal, 7171 Frederick-Banting, Saint-Laurent, Montreal, Québec H4S 1Z9 (CA).

(74) Agent: **AstraZeneca**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC COMPOUNDS



I

(57) Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein R¹, R², R³, R⁴, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.